Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692897 · ClinicalTrials.gov registry record
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
A clinical trial, sponsored by Target PharmaSolutions.
- Terminated
- Registry status
- 1,708
- Enrollment target
NCT03692897: Clinical Trial study, sponsored by Target PharmaSolutions.
NCT03692897 is a clinical trial that was terminated before completion, run by Target PharmaSolutions. The registered enrollment target is 1,708 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03692897 was terminated before completion, sponsored by Target PharmaSolutions.
- TERMINATED
- Registry status
- 1,708 participants
- Enrollment target
Study Summary
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.
Interventions
- OTHER All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,708 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2025-09-10 |
Why NCT03692897 stopped before completion
NCT03692897 is an observational study that tracks outcomes without assigning an intervention. Its 1,708 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which All approved therapies for the treatment of Chronic Hepatitis B (CHB) is the first listed.
NCT03692897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03692897 about?
NCT03692897 is a clinical study titled "An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection". The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) d...
What is the current status of trial NCT03692897?
This trial is currently terminated. The enrollment target is 1,708 participants. The study started on 2018-10-11. Estimated completion is 2025-09-10.
What interventions are being tested in trial NCT03692897?
The interventions under investigation include: All approved therapies for the treatment of Chronic Hepatitis B (CHB) (OTHER).
Who is sponsoring clinical trial NCT03692897?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI